Zenlabs Ethica

Why is Zenlabs Ethica Ltd falling/rising?

As of 31-Aug, Zenlabs Ethica Ltd's stock price is at 29.87, reflecting an 18.06% increase. This rise is driven by strong relative performance, significant weekly gains, and robust year-to-date returns, despite a decline in investor participation.

As of 31-Aug, Zenlabs Ethica Ltd's stock price is rising, currently at 29.87, which reflects an increase of 4.57 or 18.06%. This upward movement can be attributed to several factors. The stock has outperformed its sector by 18.98% today, indicating strong relative performance. Additionally, over the past week, the stock has seen a significant increase of 19.29%, while the benchmark Sensex has decreased by 0.53%. <BR><BR>The stock also experienced high volatility today, with an intraday volatility of 8.23%, and it reached an intraday high of Rs 30, marking an increase of 18.58%. Furthermore, despite a wide trading range of Rs 4.57, the stock's performance has been robust compared to the broader market, as evidenced by its year-to-date return of 50.10%, while the Sensex has declined by 9.70% during the same period.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 76.16% against the 5-day average. Despite this, the overall positive performance metrics and the stock's ability to maintain prices above key moving averages suggest a strong upward trend in the current market environment.

Who are in the management team of Zenlabs Ethica?

The management team of Zenlabs Ethica includes Sanjeev Kumar (Managing Director & CEO), Him Jyoti (Director), Ashok Kumar Gupta (Independent Director), Sanjay Dhir (Whole Time Director & CFO), Anurag Malhotra (Independent Director), Kuldeep Singh (Director), Hitesh Popatlal Oswal (Executive Director), and Akshay Saxena (Company Secretary & Compliance Officer).

The management team of Zenlabs Ethica includes the following individuals:<BR><BR>1. **Sanjeev Kumar** - Managing Director & CEO<BR>2. **Him Jyoti** - Director<BR>3. **Ashok Kumar Gupta** - Independent Director<BR>4. **Sanjay Dhir** - Whole Time Director & CFO<BR>5. **Anurag Malhotra** - Independent Director<BR>6. **Kuldeep Singh** - Director<BR>7. **Hitesh Popatlal Oswal** - Executive Director<BR>8. **Akshay Saxena** - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Zenlabs Ethica do?

Zenlabs Ethica Ltd is a micro-cap company in the diversified commercial services industry, previously known as Neelkanth Technologies Limited. As of June 2026, it reported net sales of 14 Cr and a net loss of 1 Cr, with a market cap of INR 16 Cr.

Overview: <BR>Zenlabs Ethica Ltd operates in the diversified commercial services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Zenlabs Ethica Ltd was initially incorporated as Neelkanth Technologies Limited in 1993. The company changed its name to Zenlabs Ethica Limited in the financial year 2016-17. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 14 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap: INR 16 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.29 <BR>Return on Equity: -5.41% <BR>Price to Book: 1.94 <BR><BR>Contact Details: <BR>Address: Plot No 194-195 3rd Flr Pha-II, Industrial Area Ram Darbar Chandigarh Chandigarh ( U T ) : 160002 <BR>Tel: 91-172-4651105/3920738 <BR>Email: queries@zenlabsethica.com <BR>Website: http://www.zenlabsindia.com; www.zenlabsethica.com

Who are the peers of the Zenlabs Ethica?

Zenlabs Ethica's peers include Rapid Invest, Samyak International, Greencrest Financial, S I Capital & Finance, Sawaca Enterprises, Golech Global Finance, SW Investments, Vishvprabha Ventures, and Shangar Decor. In terms of management risk, growth, and capital structure, Zenlabs Ethica ranks below average compared to some peers, with a 1-year return of -2.42%.

Peers: The peers of Zenlabs Ethica are Rapid Invest., Samyak Internati, Greencrest Finan, S I Cap. & Fin., Sawaca Enterpri., Golech.Glob.Fin., SW Investments, Vishvprabha Ven., and Shangar Decor.<BR><BR>Quality Snapshot: Excellent management risk is observed at Greencrest Finan, S I Cap. & Fin., and Golech.Glob.Fin., while Below Average management risk is found at Rapid Invest., Samyak Internati, Sawaca Enterpri., Zenlabs Ethica, Vishvprabha Ven., Shangar Decor, and the rest. Growth is Excellent at Greencrest Finan, Good at S I Cap. & Fin. and Shangar Decor, Average at Rapid Invest., Samyak Internati, Golech.Glob.Fin., and Vishvprabha Ven., while Below Average growth is noted at Sawaca Enterpri. and Zenlabs Ethica. Capital Structure is Excellent for Rapid Invest., Samyak Internati, Greencrest Finan, S I Cap. & Fin., Golech.Glob.Fin., and Zenlabs Ethica, while Below Average is seen at Sawaca Enterpri. and Shangar Decor.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Golech.Glob.Fin. at 11.31%, while the lowest is Samyak Internati at -24.88%. Zenlabs Ethica's 1-year return of -2.42% is better than Samyak Internati's but worse than Golech.Glob.Fin.'s. Additionally, Sawaca Enterpri. and Vishvprabha Ven. have negative six-month returns.

How big is Zenlabs Ethica?

As of 31st August, Zenlabs Ethica Ltd has a market capitalization of 16.00 Cr and reported net sales of 49.62 Cr with a loss of 2.54 Cr over the latest four quarters. The company has shareholder's funds of 10.43 Cr and total assets of 40.38 Cr as of March 2025.

As of 31st August, Zenlabs Ethica Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Zenlabs Ethica reported net sales of 49.62 Cr. However, the company faced a loss of 2.54 Cr during the same period.<BR><BR>For the latest annual period ending in March 2025, Zenlabs Ethica had shareholder's funds amounting to 10.43 Cr and total assets of 40.38 Cr.

Which are the latest news on Zenlabs Ethica?

Should I buy, sell or hold Zenlabs Ethica Ltd?

When is the next results date for Zenlabs Ethica Ltd?

The next results date for Zenlabs Ethica Ltd is 12 August 2026.

The next results date for Zenlabs Ethica Ltd is scheduled for 12 August 2026.

Are Zenlabs Ethica Ltd latest results good or bad?

Zenlabs Ethica Ltd's latest results are poor, showing a net profit of ₹0.00 crores and an 18.55% decline in revenue year-on-year, alongside a shrinking operating margin and low return on equity. Investors should be cautious due to the company's deteriorating financial health and high valuation relative to industry standards.

Zenlabs Ethica Ltd's latest results indicate a troubling performance. In Q4 FY26, the company reported a net profit of ₹0.00 crores, reflecting a complete collapse in profitability with a 100% decline year-on-year. Revenue also fell significantly, down 18.55% year-on-year to ₹10.58 crores, marking the weakest quarterly performance in the available dataset. Additionally, the operating margin shrank to 2.65%, down from 5.08% in the same quarter last year.<BR><BR>The overall financial health of the company appears to be deteriorating, with a negative trajectory in key metrics. The return on equity (ROE) stands at a mere 6.60%, which is below industry standards, indicating inefficiency in generating returns for shareholders. Furthermore, the company's valuation is concerning, trading at a high P/E ratio of 102.32x, which is significantly above the industry average of 23x.<BR><BR>While the stock has shown extreme volatility, surging 89.80% year-to-date, this price movement seems disconnected from the underlying business fundamentals, raising questions about sustainability. The lack of institutional interest and the presence of significant operational challenges suggest that the recent stock performance may be speculative rather than indicative of a turnaround in the company's fortunes.<BR><BR>In summary, the latest results for Zenlabs Ethica Ltd are decidedly bad, characterized by declining revenues, zero profitability, and weak operational metrics. Investors should approach with caution given the significant risks highlighted by these financial results.

How has been the historical performance of Zenlabs Ethica?

Zenlabs Ethica has experienced a decline in net sales and profits from Mar'22 to Mar'25, with net sales dropping from 69.09 Cr to 51.42 Cr and profit after tax decreasing from 1.26 Cr to 0.27 Cr. However, cash flow from operations improved significantly, rising to 3.00 Cr in Mar'25 from a negative 9.00 Cr in Mar'24.

Answer:<BR>The historical performance of Zenlabs Ethica shows a declining trend in net sales and profit over the past few years, with net sales decreasing from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25. Operating profit (PBDIT) also saw fluctuations, peaking at 3.04 Cr in Mar'23 before falling to 2.61 Cr in Mar'25. Profit before tax decreased from 1.89 Cr in Mar'19 to 0.43 Cr in Mar'25, while profit after tax declined from 1.26 Cr in Mar'19 to 0.27 Cr in Mar'25. The earnings per share (EPS) reflected this downward trend, decreasing from 1.94 in Mar'19 to 0.41 in Mar'25. <BR><BR>In terms of assets and liabilities, total assets increased from 33.65 Cr in Mar'20 to 40.38 Cr in Mar'25, while total liabilities also rose from 31.75 Cr in Mar'21 to 40.38 Cr in Mar'25. The company maintained a consistent share capital of 6.51 Cr over the years, and reserves grew from 0.90 Cr in Mar'20 to 3.92 Cr in Mar'25. Cash flow from operating activities improved to 3.00 Cr in Mar'25 from a negative 9.00 Cr in Mar'24, indicating a recovery in operational cash generation. Overall, while Zenlabs Ethica has experienced challenges in revenue and profit, there are signs of improvement in cash flow from operations.<BR><BR>Breakdown:<BR>Zenlabs Ethica's financial performance has shown a notable decline in net sales, which fell from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25, reflecting a consistent downward trend over the years. Total operating income mirrored this decline, decreasing from 69.09 Cr to 51.42 Cr in the same period. Operating profit (PBDIT) peaked at 3.04 Cr in Mar'23 but subsequently dropped to 2.61 Cr in Mar'25. Profit before tax also decreased significantly from 1.89 Cr in Mar'19 to 0.43 Cr in Mar'25, while profit after tax fell from 1.26 Cr to 0.27 Cr over the same timeframe. Earnings per share (EPS) declined from 1.94 in Mar'19 to 0.41 in Mar'25, indicating reduced profitability for shareholders. On the balance sheet, total assets increased from 33.65 Cr in Mar'20 to 40.38 Cr in Mar'25, alongside a rise in total liabilities from 31.75 Cr to 40.38 Cr. The company maintained a stable share capital of 6.51 Cr and saw its reserves grow from 0.90 Cr to 3.92 Cr. Notably, cash flow from operating activities improved to 3.00 Cr in Mar'25, recovering from a negative 9.00 Cr in Mar'24, suggesting a positive shift in operational cash generation despite the overall challenges in revenue and profit.

Who are the top shareholders of the Zenlabs Ethica?

The top shareholders of Zenlabs Ethica are Preet Remedies Limited with 26.58%, followed by public shareholder Hitesh Popatlal Oswal at 6.79%. Individual investors collectively own 41.03%, with no mutual funds or foreign institutional investors holding shares.

The top shareholders of Zenlabs Ethica include Preet Remedies Limited, which holds the largest share at 26.58%. The highest public shareholder is Hitesh Popatlal Oswal, with a holding of 6.79%. Additionally, individual investors collectively hold 41.03% of the company's shares. There are no mutual funds or foreign institutional investors (FIIs) currently holding shares in the company.

Is Zenlabs Ethica overvalued or undervalued?

As of April 26, 2023, Zenlabs Ethica is considered very expensive and overvalued, with a PE ratio of 21.71, an EV to EBIT of 25.09, a low ROE of 2.59%, and a PEG ratio of 0.00, while its stock has underperformed the Sensex with a return of -21.76% compared to the Sensex's 7.61%.

As of 26 April 2023, the valuation grade for Zenlabs Ethica has moved from does not qualify to very expensive, indicating a significant shift in its valuation outlook. The company is currently assessed as overvalued. Key ratios include a PE ratio of 21.71, an EV to EBIT of 25.09, and a ROE of 2.59%, which highlight its high valuation relative to its earnings and equity returns.<BR><BR>In comparison to its peers, Zenlabs Ethica's PE ratio is notably higher than Life Insurance, which stands at 12.54, and Bajaj Finserv, with a PE of 35.83, indicating that while it is expensive, it is not the highest in its category. The PEG ratio of 0.00 suggests that there is no growth expected, further supporting the overvaluation claim. Additionally, Zenlabs Ethica's stock has underperformed against the Sensex over the past year, with a return of -21.76% compared to the Sensex's 7.61%, reinforcing the notion that the stock may be overpriced at its current valuation.

What is the technical trend for Zenlabs Ethica?

As of May 23, 2025, Zenlabs Ethica's trend is mildly bearish, with mixed indicators showing a mildly bullish weekly MACD but a bearish monthly MACD and daily moving averages.

As of 23 May 2025, the technical trend for Zenlabs Ethica has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands on a monthly basis are bearish, further supporting the overall bearish sentiment. The KST shows a mildly bullish trend weekly but is bearish monthly, indicating mixed signals. The Dow Theory reflects a mildly bullish trend on the weekly chart but shows no trend on the monthly chart. Overall, the current stance is mildly bearish with some mixed indicators, particularly in the weekly time frame.

What is the bonus history of the Zenlabs Ethica?

Zenlabs Ethica's bonus history includes a 1:20 bonus share announcement on October 11, 2018, with a record date of October 13, 2018, meaning shareholders received 1 additional share for every 20 shares held.

Zenlabs Ethica has a bonus history that includes a notable issue on October 11, 2018. The company announced a bonus in the ratio of 1:20, which means that for every 20 shares held, shareholders received 1 additional share. The record date for this bonus was October 13, 2018. If you have any more questions about Zenlabs Ethica or need further details, feel free to ask!

Has Zenlabs Ethica declared dividend?

Zenlabs Ethica Ltd has declared a 2% dividend, amounting to 0.2 per share, with an ex-date of July 29, 2022. However, the total returns over various periods have been negative, and the dividend yield remains at 0%.

Zenlabs Ethica Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.2<BR>- Ex-date: Jul-29-2022<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -21.35%, the dividend return was 0%, resulting in a total return of -21.35%.<BR><BR>In the 1 year period, the price return was -23.56%, the dividend return was 0%, leading to a total return of -23.56%.<BR><BR>In the 2 years period, the price return was -29.74%, the dividend return was 0%, which resulted in a total return of -29.74%.<BR><BR>In the 3 years period, the price return was -1.39%, the dividend return was 0.50%, culminating in a total return of -0.89%.<BR><BR>In the 4 years period, the price return was 2.57%, the dividend return was 0.54%, resulting in a total return of 3.11%.<BR><BR>In the 5 years period, the price return was 31.82%, the dividend return was 0.98%, leading to a total return of 32.8%.<BR><BR>Overall, while Zenlabs Ethica Ltd has declared a dividend, the total returns over various periods show significant negative performance, particularly in the shorter terms, with only a modest recovery in the longer term. The dividend yield remains at 0%, indicating limited income generation from dividends relative to the share price.